Abstract. Melanoma differentiation associated gene-7 (MDA-7)/interleukin-24 (IL-24) has been considered as a tumorsuppressor gene, which suppresses the growth and induces the apoptosis of cancer cells. In the present study, we investigated the effect and mechanisms of MDA-7/IL-24 regarding the inhibition of metastasis of HepG2 and BEL-7402 human hepatocellular carcinoma (HCC) cells in vitro. We established MDA-7/IL-24-overexpressing HepG2 and BEL-7402 cell lines and found that MDA-7/IL-24 overexpression inhibited tumor cell adhesion and invasion, and induced G2/M arrest in tumor cells. To explore its mechanism of action, western blotting and real-time-PCR assay were used to investigate the expression of E-cadherin, CD44, ICAM-1, matrix metalloproteinase (MMP)-2 and -9, CyclinB, Twist, survivin, p-ERK and p-Akt. ELISA assay was used to measure the secretion of TGF-β, and a reporter gene assay was used to detected the transcriptional activity of NF-κB and AP-1 in HepG2 and BEL-7402 cells. The results showed that MDA-7/IL-24 overexpression decreased the expression of CD44, ICAM-1, MMP-2/-9, CyclinB, Twist, survivin, TGF-β and p-Akt, transcriptional activity of NF-κB, and increased the expression of E-cadherin and p-ERK and transcriptional activity of AP-1 in HepG2 and BEL-7402 cells. Our results revealed that MDA-7/IL-24 mediated the inhibition of adhesion and invasion in HepG2 and BEL-7402 cells by suppressing metastasis-related gene expression. Thus, MDA-7/ IL-24 may be used as a novel cancer-suppressor gene for the therapy of human HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality and exhibits high metastatic potential and is associated with poor patient prognosis. More than 700,000 cases of HCC were diagnosed in 2008 (1) (2) (3) . Melanoma differentiation associated gene-7 (MDA-7)/ interleukin-24 (IL-24) is a member of the IL-10 gene family, and several reports have indicated that MDA-7/IL-24 overexpression causes tumor growth suppression and tumor cell apoptosis in mesotheliomas, osteosarcoma, melanoma, lung cancer, breast cancer, pancreatic cancer, glioblastoma and prostate cancer (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , suggesting that MDA-7/IL-24 may prove to be a potential strategy for cancer therapy. However, the mechanisms through which MDA-7 expression exerts its anti-neoplastic activity, tumor-specificity and efficacy across a spectrum of human cancer types have yet to be fully elucidated. We, therefore, aimed to investigate the effect of the ectopic production of MDA-7/IL-24 on the metastasis of HCC HepG2 and BEL-7402 cells in vitro and attempted to identify the underlying mechanisms involved in its suppression of metastasis.
In the present study, we demonstrated for the first time that MDA-7/IL-24 inhibits the adhesion and invasion of HCC HepG2 and BEL-7402 cells by downregulating the expression of CD44, ICAM-1, CyclinB, Twist, survivin, p-Akt and matrix metalloproteinases (MMPs), and by upregulating the expression of E-cadherin and p-ERK. Furthermore, we confirmed that MDA-7/IL-24 reduced the secretion of TGF-β and the transcriptional activity of NF-κB and increased the transcriptional activity of AP-1 in HepG2 and BEL-7402 cells. Thus, MDA-7/IL-24 may provide multiple benefits as an anticancer therapeutic strategy due to its inhibition of tumor metastasis.
Materials and methods
Cell culture. Human HCC cell lines HepG2 and BEL-7402 were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA), and the cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (10% FBS) under conditions of 37˚C and 5% CO 2 .
Plasmid construction. The mda-7/IL-24 coding sequences were amplified by RT-PCR. The primers were: sense 1, 5'-AATAGGGCTAGCGCCACCATGAATTTTCAACAGAG GCT-3' and sense 2, 5'-GAATTCGGTCTCCTCGAGGAGC TTGTAGAATTTCTGCA-3' and were verified and ligated into the pcDNA3.1 vector (Invitrogen). Cell cycle analysis. Cells were cultured, treated with serumfree DMEM for 24 h for synchronization, and ixed in 70% ethanol at 4˚C overnight. Cells were then resuspended and incubated with 1 mg/ml of RNase A and 0.5 mg/ml propidium iodide for 30 min in the dark. Cell cycle analysis was analyzed by flow cytometry, and the percentage of cells at each phase of the cell cycle was determined using MultiCycle software.
MDA-7/IL
ELISA assay. The cell culture supernatant was collected and added to a microplate. The anti-TGF-β antibody was then added and incubation was carried out at 37˚C for 30 min. HRP was added and incubation was carried out at 37˚C for 30 min after washing with wash buffer. TMB was added and incubated at room temperature for 20 min in the dark. The absorbance was read at 450 nm after the stop solution was added, and the TGF-β content was calculated using a standard curve.
Real-time quantitative PCR. Total RNA was isolated by TRIzol assay, and real-time-PCR assays were performed by SYBR-Green incorporation. The relative gene expression was determined by duct calculation utilizing actin for normalization. GAPDH was used as a reference gene. The following primers were used to amplify cDNA fragments: human E-cadherin, (forward Western blot analysis. The cells were lysed and analyzed using 12% SDS-PAGE. The proteins were transferred to polyvinylidene difluoride membranes and blocked at 4˚C overnight with 5% milk and incubated with the monoclonal antibodies against: MDA-7/IL-24 (1:800), ICAM-1 (1:800), MMP-2 (1:800), MMP-9 (1:500), CyclinB (1:500), E-cadherin (1:800), CD44 (1:500), Twist (1:500), survivin (1:500), p-ERK (1:800), ERK (1:800), p-Akt (1:800), Akt (1:800) and mouse monoclonal β-actin (1:2,000). The results were visualization using a chemiluminescence detection kit.
Reporter gene assay. Cells were transfected with pAP-1-luc or pNFκB-luc and pRL-SV40 and plated in a 24-well plate at 1x10 5 cells/well at 37˚C. The cells were then counted by luciferase assay after 24 h.
Statistical analysis. Data are presented as the means ± standard deviation (SD) and were evaluated with SPSS 11.0. Analysis of variance was performed by one-way ANOVA, and differences were considered significant at P<0.05.
Results

Expression of the MDA-7/IL-24 gene in the establishment of stable HepG2 and BEL-7402 cells.
The transfection efficiency of HepG2 and BEL-7402 cells was measured by western blotting. The protein expression in the Ad.mda-7-1 and Ad.mda-7-2 groups was higher when compared with the expression in the Ad.vec and parent groups (Fig. 1) .
MDA-7/IL-24 inhibits tumor cell adhesion and invasive potential in HepG2 and BEL-7402 cells.
We assessed the ability of MDA-7/IL-24 to inhibit cell adhesion in HepG2 and BEL-7402 cell lines. HCC cells overexpressing MDA-7/IL-24 were significantly less able to adhere when compared to the empty vector or control groups (Fig. 3) . Furthermore, HepG2 and BEL-7402 cells overexpressing MDA-7/IL-24 were much less invasive than that of the empty vector or control groups (Fig. 2) , indicating that MDA-7/IL-24 effectively inhibits tumor cell adhesion and invasive potential in HepG2 and BEL-7402 cells.
MDA-7/IL-24 regulates expression of metastasis-related genes in HepG2 and BEL-7402 cells.
We next examined the regulatory effect of MDA-7/IL-24 on tumor metastasis-related genes which influence tumor adhesion and invasion by western blot analysis and RT-PCR assay. The results showed that the expression levels of CD44, ICAM-1, MMP-2/-9, CyclinB, Twist, survivin and p-Akt in MDA-7/IL-24-overexpressing cells were significantly decreased when compare to these levels in the empty vector or control groups at the transcription and translation levels. Moreover, the expression of E-cadherin and p-ERK was significantly increased (Figs. 4 and 5) . The results revealed that MDA-7/IL-24 inhibits expression of tumor metastasis-related genes in HepG2 and BEL-7402 cells.
MDA-7/IL-24 inhibits the TGF-β production in tumor cells.
We used ELISA assay to detect the expression of TGF-β. Results showed that production of TGF-β was decreased in the HepG2 and BEL-7402 cells overexpressing MDA-7/IL-24, when compared with the production in the empty vector negative control or parent groups (Fig. 6) . 
MDA-7/IL-24 induces accumulation of tumor cells in the G2/M phase of the cell cycle.
As shown in Fig. 7 
MDA-7/IL-24 downregulates the transcriptional activation of AP-1 and NF-κB in the HepG2 and BEL-7402 cells.
We examined the effect of MDA-7/IL-24 on the transcriptional activation of AP-1 and NF-κB in HepG2 and BEL-7402 cells by luciferase reporter assay. We found that MDA-7/IL-24 downregulated the transcriptional activation of NF-κB and upregulated the transcriptional activation of AP-1 in HepG2 and BEL-7402 cells (Fig. 8) .
Discussion
MDA-7/IL-24 is a cytokine-like protein of the IL-10 cytokine family and has been reported to decrease survival in adjacent tumor cells while sparing normal cells (17) (18) (19) (20) . The present study adds to the literature findings regarding the metastatic inhibitory function of MDA-7/IL-24 in solid human malignancies, with particular reference to HCC. In the present study, the results revealed that MDA-7/IL-24 inhibited the potential of adhesion and invasion of human HCC HepG2 and BEL-7402 cells, and the invasion and adhesion inhibition ability of the cells was enhanced along with the increased expression of MDA-7/IL-24. Several reports have demonstrated that MDA-7/IL-24 overexpression results in growth inhibition and apoptosis in many types of cancer. MDA-7/IL-24 is considered as an ideal gene for tumor gene therapy due to its low deleterious effects on normal cells (21) . We transfected the MDA-7/IL-24 expression plasmid into HepG2 and BEL-7402 cell lines, and western blot assay showed that MDA-7/IL-24 was overexpressed in cells transfected with Ad.mda-7-1 and Ad.mda-7-2, while the parental and Ad.vec groups did not show protein overexpression. MDA-7/IL-24 induces tumor-suppressive activity through multiple mechanisms. In order to explore its mechanisms, we investigated the protein and mRNA expression of E-cadherin, CD44, ICAM-1, CyclinB, Twist, survivin, p-ERK and p-Akt in tumor cells. The results indicated that MDA-7/IL-24 overexpression decreased the expression of CD44, ICAM-1, CyclinB, Twist, survivin and p-Akt, while the expression of E-cadherin and p-ERK was upregulated.
E-cadherin, CD44 and ICAM-1 are known as significant adhesion molecules, and are necessary for cell adhesion, migration, proliferation, apoptosis and cell signal transmission (22) . Overexpression of MDA-7/IL-24 induced the downregulation of CD44/ICAM-1 and the upregulation of E-cadherin, indicating that one mechanism involved in the suppression of tumor cell adhesion and invasion by MDA-7/IL-24 is through the regulation of the expression of adhesion molecules.
CyclinB is a key protein in cell cycle regulation by regulating cytoskeletal dynamics. Recent research suggests that CyclinB may regulate tumor growth, invasion and metastasis, and upregulation of CyclinB expression increases tumor metastasis potential. MDA-7/IL-24 induced the accumulation of HepG2 and BEL-7402 cells in the G2/M phase of the cell cycle. Twist is a transcription factor which relies on the basic DNA-binding region and the helix-loop-helix structure that allows monomers to form functional dimers that can identify and bind to the E-box DNA motif. Twist has been considered to inhibit E-cadherin expression, promote tumor cell adhesion and invasion. Survivin promotes cell adhesion and invasion by cell cycle-related kinases and regulation of the cell division process. Our results suggest that MDA-7/IL-24 suppresses tumor adhesion and invasion by controlling the expression of E-cadherin, CD44, ICAM-1, CyclinB, Twist and survivin and that together they are important to human HCC metastasis.
The activity of proteolysis enzymes is attributed to degradation of the tumor cell extracellular matrix (ECM). Among the proteases implicated in tumor cell dissemination are the MMPs (23), which are required by cells for tissue remodeling. However, the production of MMPs has been observed in many invasive tumor cell lines and during tumor growth (24) . In fact, MMP-2/-9 levels appear to be prognostically significant during tumor progression in many tumor types (11, (25) (26) (27) , and the extent of MMP overproduction correlates with prognosis. Therefore, we investigated and found that MDA-7/IL-24 overexpression decreased the expression of MMP-2/-9 at the protein and mRNA levels. Additionally, MDA-7/IL-24 influenced TGF-β activity in tumor cells. ELISA assay was used to investigate the secretion of TGF-β in HCC cancer cells, and we found that MDA-7/IL-24 induced the downregulation of TGF-β.
NF-κB is a transcription factor which upregulates many types of metastasis-related genes, and research has demonstrated that NF-κB regulates tumor metastasis potential. AP-1 is composed of the c-Jun and c-fos and also controls numerous genes contributing to the process of tumor metastasis. We hypothesized the regulatory role of MDA-7/IL-24 in the control of the NF-κB and AP-1 transcription activation and demonstrated that MDA-7/IL-24 suppresses tumor metastasis potential by regulating their transcription activation.
Additionally, we explored the contribution of MDA-7/IL-24 on tumor metastasis signaling molecules. Numerous reports have shown that Akt and ERK are involved in the processes of adhesion and invasion in many types of tumors, and also control expression of transcription factors. In the present study, we examined the effect of MDA-7/IL-24 on the Akt and ERK pathway and demonstrated that MDA-7/IL-24 regulates Akt and ERK phosphorylation (28, 29) . Therefore, we presumed that the modulation of the Akt and ERK signaling pathway contributing to the AP-1 and NF-κB transcriptional activation regulation is the basis for the suppression of tumor metastasis by MDA-7/IL-24.
In conclusion, we demonstrated for the first time that MDA-7/IL-24 inhibits the metastatic potential of human HepG2 and BEL-7402 cells in vitro. Thus, MDA-7/IL-24 may provide an effective therapeutic strategy for HCC and may reduce tumor metastasis.
